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versely related to patient age (p 
 

 
 .0029), tamoxifen var-
ied directly with patient age (p 
 

 
 .0002) but inversely
with physician age (p  .02), and adjuvant chemotherapy
and taxoids varied inversely with patient age (p  .0001).
CONCLUSIONS: Two decades of multiple randomized
control trials and meta-analyses have led to only modest
success in the use of highly beneficial treatments for
breast cancer in these specific oncology practices, al-
though non-beneficial treatments are almost never used.
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REGIONAL VARIATION IN PRESCRIPTION USE 
IN THE UNITED STATES
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OBJECTIVE:
 
 To evaluate the factors influencing the utiliza-
tion of prescribed medications across the United States.
 
METHODS:
 
 Prescription claims data for a random sam-
ple of commercially insured Express Scripts members, 18
to 64 years of age and continuously eligible for at least
two months in 1999 (N  1,467,699), were geo-coded at
the block group level. Key independent variables included
age, gender, family size, median income, education, ur-
ban/rural location, client type, and pharmacy benefit de-
sign. Outcome measures included any use of prescrip-
tions. Hierarchical modeling (HLM) was used to control
for clustering of patients within health plans.
RESULTS: Results from HLM indicate that after control-
ling for demographics, client type, and pharmacy benefit
design, variation in the probability of using a prescribed
medication was found across regions of the country.
Members in the South have a greater likelihood of use
and members in the Northeast and West having a lower
probability of use than members in the Midwest. A
greater probability of use was associated with older age,
female gender, higher income, family size 1, and enroll-
ment in a managed care plan. Factors associated with
lower probability of prescription use included presence of
a deductible, living in an urban area and having a manda-
tory generic policy.
CONCLUSIONS: While patient age and gender remain
key factors driving prescription utilization, socioeconom-
ics, pharmacy benefit design, and where a person lives are
also predictors of prescription use. Future research is
needed to better understand the causative roles of disease
burden, physician practice style, and consumer preferences
in prescription drug use variation across the United States.
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OBJECTIVE:
 
 The objective of this study was to derive a
brief, clinically relevant symptom index for men with
HRPCa.
 
METHODS:
 
 An international sample of 44 medical on-
cologists, radiation oncologists, and urologists were pre-
sented with 29 disease-related symptoms derived from
the Functional Assessment of Cancer Therapy-Prostate
(FACT-P) quality of life (QOL) instrument and asked to
select the five most important symptoms in assessing the
treatment response for men with HRPCa. Symptoms en-
dorsed at a frequency greater than chance were retained
for the index. Retrospective validation of the index was
accomplished using data from a multi-national, random-
ized, double-blind, placebo-controlled clinical trial of
atrasentan, a selective, oral ET-A receptor antagonist.
The FACT-P and European Organization for Research
and Treatment of Cancer (EORTC) QLQ-C30 adminis-
tered at baseline, six weeks and final visit were used to
evaluate QOL responses to treatment of 288 men with
HRPCa.
RESULTS: Experts initially selected eight priority symp-
toms. Item-Response Theory analysis identified one mis-
fitting item (worry), lending support for a seven-item in-
dex (FPSI-7). Internal consistency was high for the seven-
item index (0.75). Concurrent validity was established
through correlations (P  0.05) between the FPSI-7 and
the FACT-General (FACT-G; r  0.56); FACT-P (r 
0.73); FACT Prostate Cancer Subscale (PCS; r  0.88);
Trial Outcome Index (TOI; r  0.83); and QLQ-C30
global score (r  .56), symptom domain scores (r 
0.33 to 0.76), and generic domain scores (r  0.36 to
0.60). The FPSI-7 successfully differentiated patients by
functional status, measured by the Eastern Cooperative
Oncology Group (ECOG) performance status rating
(PSR, p  .001), and clinical outcome, measured by dis-
ease progression status (p  .001). PSR and disease pro-
gression are important outcomes for patients and clinical
trials. The FPSI-7’s responsiveness to PSR change com-
pared favorably to the FACT-G, PCS, FACT-P and TOI.
CONCLUSION: The FPSI-7 is a valid and responsive
symptom index that can provide efficient, rapid symptom
assessment to evaluate treatment outcome in clinical trials.
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RESOURCE CONSUMPTION RELATED TO 
MUCOSITIS IN LYMPHOMA PATIENTS 
RECEIVING HIGH-DOSE CHEMOTHERAPY WITH 
AUTOLOGOUS PBPC TRANSPLANTATION
 
Chan WW, Lawless G
Amgen Inc, Thousand Oaks, CA, USA
OBJECTIVES: To evaluate resource consumption related
to mucositis in lymphoma patients receiving high-dose
chemotherapy (HDC) with autologous PBPC transplan-
tation.
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METHODS:
 
 Data on mucositis and clinical parameters
of hospitalization, IV antibiotic use, fever, analgesic use,
and parenteral nutrition were collected as part of a multi-
center clinical trial conducted in Europe (n  234). Pa-
tients were quantified as having mucositis if ulcerative
lesions were present after receiving BEAM (BCNU, Eto-
poside, Ara-C, Melphalan) HDC. Days of usage for clini-
cal parameters were quantified as resource consumption
and compared in patients with and without mucositis.
RESULTS: Mucositis showed an association with resource
consumption. Days of analgesia had the highest correla-
tion followed by antibiotic use, fever, hospitalization, and
parenteral nutrition (r  0.4128*, 0.3003*, 0.2634*,
0.2558*, 0.0973, respectively, *p  .0001). Patients with
mucositis had two additional days of hospitalization and
three additional days of IV antibiotics. Mean  s.e. for re-
source consumption is listed for patients (with mucositis,
without mucositis, p-value), as follows: days of hospital-
ization (26.8  0.4, 24.4  0.5, p  .001); days of IV an-
tibiotics (12.6  0.7, 9.5  0.7, p  .002); days of anal-
gesic use (9.2  0.7, 4.3  0.5, p  .001); days of
parenteral nutrition (1.8  0.3, 1.6  0.2, p  .668);
days of fever (2.9  0.3, 2.0  0.3, p  .035).
CONCLUSIONS: Patients with mucositis had signifi-
cantly higher resource consumption. Mucositis impacts
on length of hospitalization, days of fever, IV antibiotic,
and analgesic use.
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OBJECTIVES:
 
 The majority of patients with non-small
cell lung cancer (NSCLC) present with advanced disease,
for which pharmacological therapy is the primary treat-
ment option. Economic models are useful tools to help
decision-makers determine the cost and health impact of
existing and new therapies in their practice settings.
METHODS: A decision-analytic model was developed to
represent the progression of advanced (stage IIIB/IV)
NSCLC from diagnosis and first-line therapy to subse-
quent lines of therapy, best supportive care and death.
The model is a semi-Markov process with three-week cy-
cles and a two-year time horizon. By selecting different
sets of model parameters, it may be used to estimate cost-
of-illness (by pooling cost and health outcomes across a
range of therapies), cost-effectiveness (comparison be-
tween new or existing therapeutic options) and impact on
health-care budgets. Data sources include published clini-
cal trials, treatment patterns based on published studies,
and a panel of US clinicians and US unit costs. In this
case, the NSCLC model was used to examine the costs
and outcomes of a distribution of mono and combination
agents most commonly administered as first and second-
line therapy in the US.
RESULTS: Over one and two years respectively the aver-
age cost of therapy was $42,319 and $48,151 per pa-
tient, with an estimated survival of 40.2% and 7.4%.
The estimated cost for a health-care purchaser with a
prevalence of 100 patients with advanced NSCLC was
$4.90 million per year. If all patients used carboplatin
and paclitaxel as first-line therapy, this increased to
$5.14 million. If a new therapy increased the median time
to progression for patients on first-line therapy by two
months, the cost increased to $5.0 million per year.
CONCLUSION: This model provides a flexible analyti-
cal platform for a range of economic evaluations of alter-
native therapeutic strategies in advanced NSCLC. This is
valuable for strategic planning in Phase II/III drug devel-
opment.
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ESTIMATING THE IMPACT OF 
ANTICOAGULATION QUALITY
ON EVENT RATES
Matchar DB, Samsa GP
Duke University, Durham, NC, USA
OBJECTIVES: Warfarin anticoagulation has been shown
to effectively decrease the rate of thromboembolism (TE),
with an associated increased rate of bleeding. Maximiz-
ing the benefit and minimizing the risk depends on main-
taining patients in a narrow therapeutic range for pro-
thrombin time (measured as INR). An increased percentage
of time spent in target range (TTR) is predictive of better
clinical outcomes. However, strategies to increase TTR can
be costly. To allow local clinical policy makers to deter-
mine whether these strategies can be justified, we developed
a general approach to estimating bleeding and TE rates as-
sociated with a given population distribution of INR.
METHODS: We used data from a large cohort (Cannegi-
eter, 1995) to derive a logistic equation for baseline abso-
lute risk of bleeding as a function of INR. Based on a sep-
arate large cohort of patients (Fihn, 1993) with various
times since initiation of therapy, we derived a risk ratio
that modifies the above baseline relationship that ac-
counts for time since initiation of therapy. A similar strat-
egy was used to estimate TE, using INR and indication
(mechanical valve versus atrial fibrillation) as predictors.
RESULTS: The model for bleeding was: logit(p)  8.84 
0.83 INR  0.64 EARLY, where EARLY  1 if the pa-
tient is in the first 3 months of anticoagulation, and 0
otherwise. The final model for TE was: logit(p)  0.73
1.17 INR  0.64(AF), where AF  1 if the indication is
atrial fibrillation and 0 if the indication is mechanical
heart valve. The integral of these logistic equations,
weighted by a given population distribution of INR, pro-
vides population estimates of annual bleed and TE rates.
